Ryan Marnie A, Akinbi Henry T, Serrano Alicia G, Perez-Gil Jesus, Wu Huixing, McCormack Francis X, Weaver Timothy E
Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, and University of Cincinnati College of Medicine, OH 45229-3039, USA.
J Immunol. 2006 Jan 1;176(1):416-25. doi: 10.4049/jimmunol.176.1.416.
Surfactant protein B (SP-B) is secreted into the airspaces with surfactant phospholipids where it reduces surface tension and prevents alveolar collapse at end expiration. SP-B is a member of the saposin-like family of proteins, several of which have antimicrobial properties. SP-B lyses negatively charged liposomes and was previously reported to inhibit the growth of Escherichia coli in vitro; however, a separate study indicated that elevated levels of SP-B in the airspaces of transgenic mice did not confer resistance to infection. The goal of this study was to assess the antimicrobial properties of native SP-B and synthetic peptides derived from the native peptide. Native SP-B aggregated and killed clinical isolates of Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, and group B streptococcus by increasing membrane permeability; however, SP-B also lysed RBC, indicating that the membranolytic activity was not selective for bacteria. Both the antimicrobial and hemolytic activities of native SP-B were inhibited by surfactant phospholipids, suggesting that endogenous SP-B may not play a significant role in alveolar host defense. Synthetic peptides derived from native SP-B were effective at killing both Gram-positive and Gram-negative bacteria at low peptide concentrations (0.15-5.0 microM). The SP-B derivatives selectively lysed bacterial membranes and were more resistant to inhibition by phospholipids; furthermore, helix 1 (residues 7-22) retained significant antimicrobial activity in the presence of native surfactant. These results suggest that the role of endogenous SP-B in host defense may be limited; however, synthetic peptides derived from SP-B may be useful in the treatment of bacterial pneumonias.
表面活性蛋白B(SP - B)与表面活性磷脂一起分泌到肺泡腔中,在那里它可降低表面张力并防止呼气末肺泡塌陷。SP - B是类鞘脂激活蛋白家族的成员之一,其中几种具有抗菌特性。SP - B可使带负电荷的脂质体溶解,此前有报道称其在体外可抑制大肠杆菌的生长;然而,另一项研究表明,转基因小鼠肺泡腔中SP - B水平升高并未赋予其抗感染能力。本研究的目的是评估天然SP - B及其衍生的合成肽的抗菌特性。天然SP - B通过增加膜通透性聚集并杀死肺炎克雷伯菌、铜绿假单胞菌、金黄色葡萄球菌和B族链球菌的临床分离株;然而,SP - B也会溶解红细胞,这表明其膜溶解活性对细菌没有选择性。表面活性磷脂可抑制天然SP - B的抗菌和溶血活性,这表明内源性SP - B可能在肺泡宿主防御中不发挥重要作用。天然SP - B衍生的合成肽在低肽浓度(0.15 - 5.0 microM)下可有效杀死革兰氏阳性菌和革兰氏阴性菌。SP - B衍生物可选择性地溶解细菌膜,并且对磷脂抑制更具抗性;此外,在存在天然表面活性剂的情况下,螺旋1(第7 - 22位氨基酸残基)仍保留显著的抗菌活性。这些结果表明内源性SP - B在宿主防御中的作用可能有限;然而,SP - B衍生的合成肽可能对治疗细菌性肺炎有用。